Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03668431 |
Title达拉非尼 + 曲美替尼 + PDR001 在结直肠癌中的应用 | 阶段
第二阶段
|
Date Added 2018-09-12 |
地点
Massachusetts, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Dabrafenib, PDR001, Trametinib, Mekinist, Tafinlar |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03667170 |
TitleKN035 for dMMR/MSI-H Advanced Solid Tumors | 阶段
第二阶段
|
Date Added 2018-09-12 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT03658785 |
Title治疗晚期实体瘤的免疫疗法 | 阶段
第 1 阶段
|
Date Added 2018-09-05 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, TIL |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03657641 |
TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2018-09-05 |
地点
California, United States
Florida, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga |
标签
MSS/ MMRp
|
| NCT ID NCT03650348 |
TitlePRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | 阶段
第 1 阶段
|
Date Added 2018-08-28 |
地点
California, United States
Louisiana, United States New York, United States Ohio, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
PRS-343 in Combination with Atezolizumab, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT03638206 |
Title治疗恶性肿瘤的自体 CAR-T/TCR-T 细胞免疫疗法 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2018-08-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
CAR-T cell immunotherapy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | 阶段
第二阶段
|
Date Added 2018-08-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
PD-1 antibody + cox inhibitor |
标签
MSI-H/ MMRd
|
| NCT ID NCT03626922 |
TitleStudy of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | 阶段
第 1 阶段
|
Date Added 2018-08-13 |
地点
Florida, United States
Illinois, United States Michigan, United States Minnesota, United States Pennsylvania, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Dexamethasone, oxaliplatin, Pembrolizumab, Pemetrexed, Alimta, Eloxatin, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03608046 |
TitleAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | 阶段
第二阶段
|
Date Added 2018-07-31 |
地点
比利时
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Avelumab, Cetuximab Injection, Irinotecan |
标签
MSS/ MMRp
|
| NCT ID NCT03600883 |
TitleA Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | 阶段
Phase 1, Phase 2
|
Date Added 2018-07-26 |
地点
California, United States
Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Indiana, United States Maryland, United States Massachusetts, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States 澳大利亚 Austria 比利时 巴西 加拿大 法国 德国 希腊 Hungary 日本 大韩民国 葡萄牙 Romania 西班牙 瑞士 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Anti PD-1/L1, Midazolam, Sotorasib |
标签
MSS/ MMRp
|
